Michael V. McCullar

Biochemistry, Genetics and Molecular Biology · Life Sciences

11h-index597citations25works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA modifications and cancer(9), Cancer, Hypoxia, and Metabolism(7), Cancer-related gene regulation(5), Cancer-related Molecular Pathways(4), Cancer Mechanisms and Therapy(4)

Publications25 total

Supplementary Figure Legends from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
2023Open Access
Supplementary Figure Legends from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
2023Open Access
Supplementary Figures 1-4 from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
2023Open Access
Data from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
2023Open Access
Data from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
2023Open Access
Supplementary Figures 1-4 from Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
2023Open Access
Targeting DNA Methylation
2015· 1 cited
Synthesis and Biological Evaluation of Pyrazolo[1,5-<i>a</i>]pyrimidine Compounds as Potent and Selective Pim-1 Inhibitors
ACS Medicinal Chemistry Letters·2014· 55 citedOpen Access
Macho mengi: Many eyes on the Universe
Journal of Aeronautics & Aerospace Engineering·2014
A Small-Molecule Inhibitor of PIM Kinases as a Potential Treatment for Urothelial Carcinomas
Neoplasia·2014· 90 citedOpen Access
Discovery of 3-(trifluoromethyl)-1H-pyrazole-5-carboxamide activators of the M2 isoform of pyruvate kinase (PKM2)
Bioorganic & Medicinal Chemistry Letters·2013· 49 cited
Discovery of Novel Putative Inhibitors of UDP-GlcNAc 2-Epimerase as Potent Antibacterial Agents
ACS Medicinal Chemistry Letters·2013· 13 citedOpen Access
Pharmacologic Activation of PKM2 Slows Lung Tumor Xenograft Growth
Molecular Cancer Therapeutics·2013· 69 cited
Synthesis and structure–activity relationship of 2-arylamino-4-aryl-pyrimidines as potent PAK1 inhibitors
Bioorganic & Medicinal Chemistry Letters·2013· 18 citedOpen Access
Discovery of 4-phenyl-2-phenylaminopyridine based TNIK inhibitors
Bioorganic & Medicinal Chemistry Letters·2012· 29 citedOpen Access
Abstract 3762: Second generation PIM inhibitors exhibit improved activity in solid tumor models
Cancer Research·2012· 1 cited
Abstract 3226: PKM2 metabolic activator slows lung cancer xenograft growth
Cancer Research·2012
Abstract C200: Second-generation PIM inhibitors exhibit improved activity in solid tumor models in vitro.
Molecular Cancer Therapeutics·2011· 1 cited
Abstract B143: PKM2 metabolic activator slows lung cancer xenograft growth.
Molecular Cancer Therapeutics·2011
Epigenetic Drug Discovery: Targeting DNA Methyltransferases
SLAS DISCOVERY·2011· 156 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Jason M. Foulks(17), Steven B. Kanner(17), Adrianne Clifford(15), Koc-Kan Ho(13), K. Mark Parnell(12), Anna V. Senina(12), Rebecca N. Nix(11), Michael Saunders(10), Jeremy Bullough(9), Virgil McCarthy(9), David Vollmer(8), Jihua Liu(8), Bai Luo(7), Marc O’Reilly(7), Bai Luo(7), Benjamin Brenning(6), Yong Xu(6), Scott Pearce(6), Kevin B. Wright(6), Shannon Merx(5)